Regeneron starts clinical trial of COVID-19 treatment

Thursday, 11. June 2020 13:33

Regeneron Pharmaceuticals Inc. announced on Thursday it started the first clinical trials of its two-antibody cocktail for the prevention and treatment of COVID-19.

The dual antibody cocktail dubbed REGN-COV2 will be tested on infected people, as well as those who have been exposed to COVID-19 patients.

"We have created a unique anti-viral antibody cocktail with the potential both to prevent and treat infection, and also to preempt viral 'escape,' a critical precaution in the midst of an ongoing global pandemic," Regeneron's chief scientific officer, George D. Yancopoulos, stated.

Related Links: Regeneron Pharmaceuticals Inc.
Breaking the News / NP